

Coherus BioSciences Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 27-Apr-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

 Phase 3 Clinical..... 11

 Phase 1 Clinical..... 17

 Clinical..... 21

 Discovery..... 23

[Return to Table of Contents](#)

Coherus BioSciences Inc

COMPANY OVERVIEW

Company Name	Coherus BioSciences Inc
Parent Company Name	Coherus BioSciences Inc
Website	http://www.coherus.com/
Country	US
Number of Drugs in Active Development	8
Number of Inactive Drugs	0
Number of Patents as Owner	9
Number of Patents as Third Party	0
Number of Deals	2
Key Indications	Unidentified indication,Rheumatoid arthritis,Psoriasis,Inflammatory disease,Febrile neutropenia,Hematological neoplasm,Ankylosing spondylitis,Psoriatic arthritis,Asthma,Atopic dermatitis,Cachexia,Chronic obstructive pulmonary disease,Crohns disease,Hepatitis C virus infection
Key Target-based Actions	TNF alpha ligand inhibitor,TNF antagonist,Type II TNF receptor modulator,B-lymphocyte antigen CD20 inhibitor,GCSF ligand,GCSF receptor agonist
Key Technologies	Biological therapeutic,Biosimilar product,Protein recombinant,Parenteral formulation unspecified,Subcutaneous formulation,Protein fusion,Liquid formulation,Monoclonal antibody human,Chimeric monoclonal antibody,Infusion,Intravenous formulation,PEGylated formulation,Systemic formulation unspecified

COMPANY PROFILE

SUMMARY

Coherus BioSciences was incorporated in Delaware in September 2010 under the name BioGenerics Inc and subsequently changed its name to Coherus BioSciences Inc in April 2012. It is a biopharmaceutical company specializing in biosimilars in the field of oncology and inflammation.

COMPANY LOCATION

Coherus is based in San Francisco, CA.

FINANCIAL

In March 2015, the company announced an underwritten public offering of \$100 million of common stock shares; underwriters were to be granted a 30-day option to purchase a further \$15 million of shares. Later that month, Coherus priced the underwritten public offering of 4,137,931 shares of its common stock at a price of \$29.00 per share. The underwriters were granted a 30-day option to purchase up to an additional 620,689 shares of common stock at the public offering price. The offering was expected to close on or about April 07, 2015.

In November 2014, the company priced its IPO of 6,296,300 shares of its common stock at \$13.50 per share, trading under ticker symbol 'CHRS', and granted the underwriters a 30-day option to purchase up to 944,445 additional common shares at the offering price. At that time, the offering was expected to close on November 12, 2014. In November 2014, the company closed the IPO of 6,803,702 of its common stock shares and included a purchase of 507,402 shares of the company's common stock by the underwriters with an option to purchase additional shares. At that time, the company expected the net proceeds to be approximately \$81.5 million.

In May 2014, the company raised \$55 million through a series C financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Unidentified indication	4	0	4
Hematological disease	2	0	2
Musculoskeletal disease	2	0	2
Inflammatory disease	2	0	2
Immune disorder	2	0	2
Dermatological disease	1	0	1
Neoplasm	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 1 Clinical	2
Clinical	1
Discovery	4

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	2	0	0	0	2

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Immune disorder	2	2
Musculoskeletal disease	1	1
Inflammatory disease	1	1
Dermatological disease	1	1

Trials by Phase

Phase	Ongoing	All
Phase 3	2	2
Phase 1	2	3
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Gastrointestinal disease	3	0	3
Genitourinary disease	2	0	2
Hematological disease	1	0	1
Degeneration	1	0	1
Immune disorder	4	0	4

[Return to Table of Contents](#)



Musculoskeletal disease	3	0	3
Neoplasm	1	0	1
Neurological disease	1	0	1
Nutritional disorder	2	0	2
Respiratory disease	3	0	3
Infectious disease	2	0	2
Inflammatory disease	4	0	4
Gynecology and obstetrics	1	0	1
Dermatological disease	4	0	4

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter

etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter SNAPSHOT

Drug Name	etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter
Key Synonyms	etanercept
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc;Baxter International Inc;Daiichi Sankyo Co Ltd
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Rheumatoid arthritis;Psoriasis;Inflammatory disease
Target-based Actions	TNF alpha ligand inhibitor;TNF antagonist;Type II TNF receptor modulator
Other Actions	Anti-inflammatory;TNF binding agent
Technologies	Biosimilar product;Biological therapeutic;Liquid formulation;Subcutaneous formulation;Protein fusion
Last Change Date	27-Apr-2015

etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter DEVELOPMENT PROFILE

SUMMARY

Coherus BioSciences, in collaboration with licensees Daiichi Sankyo and Baxter, is developing CHS-0214, a biosimilar of etanercept, a fusion protein comprising the extracellular domain of human p75 TNF receptor linked to the Fc portion of human IgG1, which acts as a TNF alpha inhibitor, for the potential treatment of inflammatory conditions including rheumatoid arthritis and psoriasis. In June 2014, a phase III study for rheumatoid arthritis was initiated. In July 2014, a phase III study for psoriasis was initiated; in August 2014, the trial was initiated in Japan. In October 2013, data were reported from a pivotal confirmatory clinical trial in healthy subjects. At that time, the company expected to initiate a second pivotal trial 'in the near future'.

etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Baxter International Inc	Psoriasis	Australia	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Psoriasis	Canada	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Psoriasis	Chile	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Psoriasis	Europe	Phase 3 Clinical	25-Sep-2014

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Baxter International Inc	Psoriasis	Germany	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Psoriasis	Israel	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Psoriasis	South Africa	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Psoriasis	US	Phase 3 Clinical	16-Jul-2014
Baxter International Inc	Rheumatoid arthritis	Argentina	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Rheumatoid arthritis	Europe	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Rheumatoid arthritis	Israel	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Rheumatoid arthritis	Japan	Phase 3 Clinical	25-Sep-2014
Baxter International Inc	Rheumatoid arthritis	US	Phase 3 Clinical	23-Jun-2014
Coherus BioSciences Inc	Psoriasis	Australia	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	Canada	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	Chile	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	Europe	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	Israel	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	South Africa	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	US	Phase 3 Clinical	16-Jul-2014
Coherus BioSciences Inc	Rheumatoid arthritis	Argentina	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Rheumatoid arthritis	Europe	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Rheumatoid arthritis	Israel	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Rheumatoid arthritis	Japan	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Rheumatoid arthritis	South Africa	Phase 3 Clinical	16-Apr-2015
Coherus BioSciences Inc	Rheumatoid arthritis	US	Phase 3 Clinical	23-Jun-2014
Daiichi Sankyo Co Ltd	Inflammatory disease	Japan	Phase 3 Clinical	18-Aug-2014
Daiichi Sankyo Co Ltd	Psoriasis	Australia	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Psoriasis	Canada	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Psoriasis	Chile	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Psoriasis	Europe	Phase 3 Clinical	25-Sep-2014

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Daiichi Sankyo Co Ltd	Psoriasis	Israel	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Psoriasis	South Africa	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	Argentina	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	Europe	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	Israel	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	Japan	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	South Africa	Phase 3 Clinical	16-Apr-2015
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	US	Phase 3 Clinical	23-Jun-2014
Baxter International Inc	Inflammatory disease	Europe	Clinical	28-Oct-2013
Coherus BioSciences Inc	Inflammatory disease	US	Clinical	28-Oct-2013
Baxter International Inc	Inflammatory disease	Brazil	Discovery	03-Sep-2013
Baxter International Inc	Inflammatory disease	Canada	Discovery	03-Sep-2013
Daiichi Sankyo Co Ltd	Inflammatory disease	South Korea	Discovery	07-May-2012
Daiichi Sankyo Co Ltd	Inflammatory disease	Taiwan	Discovery	07-May-2012

etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter DRUG NAMES

Names	Type
etanercept	BANN, INN, USAN
etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter	
CHS-0214	Research Code

etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Psoriasis											
0	0	1	1	0	0	0	0	0	0	1	1

[Return to Table of Contents](#)



Rheumatoid arthritis											
0	0	1	1	0	0	0	0	0	0	1	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	2	2	0	0	0	1	0	0	2	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Coherus BioSciences Inc	2	0	0	0	2
Daiichi Sankyo Co Ltd	0	0	1	0	1
Baxter International Inc	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	0	2

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Coherus BioSciences Inc	3	0	3

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1
Formulation	1
Process	1

[Return to Table of Contents](#)

CHS-001

CHS-001 SNAPSHOT

Drug Name	CHS-001
Key Synonyms	
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Unidentified indication
Target-based Actions	
Other Actions	Unspecified drug target
Technologies	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant
Last Change Date	24-Jul-2014

CHS-001 DEVELOPMENT PROFILE

SUMMARY

Coherus is developing CHS-001, a biosimilar version of an undisclosed product, for the potential treatment of inflammatory disorders and/or cancer. By September 2013, a phase I trial had been initiated. In January 2014, the company planned to initiate a phase III study in the second quarter of 2014, and the study was expected to complete in the fourth quarter of 2015. At that time, the company planned to file a marketing application in the third quarter of 2015.

CHS-001 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Coherus BioSciences Inc	Unidentified indication	US	Phase 1 Clinical	30-Sep-2013

CHS-001 DRUG NAMES

Names	Type
CHS-001	Research Code
undisclosed biosimilar, Coherus	

[Return to Table of Contents](#)





pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences SNAPSHOT

Drug Name	pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences
Key Synonyms	pegfilgrastim
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Febrile neutropenia
Target-based Actions	GCSF receptor agonist;GCSF ligand
Other Actions	Neutrophil stimulator;Hematopoietic stimulant
Technologies	Biosimilar product;PEGylated formulation;Biological therapeutic;Subcutaneous formulation;Protein recombinant
Last Change Date	18-Mar-2015

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences DEVELOPMENT PROFILE

SUMMARY

Coherus BioSciences is developing CHS-1701, a biosimilar version of the PEGylated granulocyte colony stimulating factor ligand pegfilgrastim, for the potential sc treatment of febrile neutropenia in breast cancer patients. In November 2012, phase I trial was initiated. In March 2013, the trial was completed. In September 2014, additional trials were being planned. At that time, the company planned to initiate a phase III trial in the first half of 2015 . In December 2014, Coherus was planning to amend the IND application in the first quarter of 2015. In September 2014, the company planned for seeking to outlicense the drug outside the US.

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Coherus BioSciences Inc	Febrile neutropenia	US	Phase 1 Clinical	30-Nov-2012

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences DRUG NAMES

Names	Type
pegfilgrastim	BANN, INN, USAN
pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences	
CHS-1701	Research Code

[Return to Table of Contents](#)

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences CLINICAL TRIALS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	2	2	0	0	2	2

[Return to Table of Contents](#)

adalimumab biosimilar, Coherus

adalimumab biosimilar, Coherus SNAPSHOT

Drug Name	adalimumab biosimilar, Coherus
Key Synonyms	adalimumab
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc
Inactive Companies	
Highest Status	Clinical
Active Indications	Rheumatoid arthritis
Target-based Actions	TNF alpha ligand inhibitor
Other Actions	TNF binding agent;Anti-inflammatory
Technologies	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Systemic formulation unspecified;Protein recombinant;Monoclonal antibody human
Last Change Date	05-Nov-2014

adalimumab biosimilar, Coherus DEVELOPMENT PROFILE

SUMMARY

Coherus BioSciences is developing CHS-1420, a humanized biosimilar version of adalimumab (Humira), for the potential treatment of rheumatoid arthritis (RA). In April 2014, phase I trial was initiated. In August 2014, trial was completed. In September 2014, the company planned to initiate a phase III trial in the US, Europe and Japan, in psoriasis or rheumatoid arthritis, in the first half of 2015. At that time, the company planned for seeking to outlicense the drug outside the US.

adalimumab biosimilar, Coherus DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Coherus BioSciences Inc	Rheumatoid arthritis	US	Clinical	14-Aug-2014

adalimumab biosimilar, Coherus DRUG NAMES

Names	Type
adalimumab	INN, USAN
CHS-1420	Research Code
adalimumab biosimilar, Coherus	

[Return to Table of Contents](#)

adalimumab biosimilar, Coherus CLINICAL TRIALS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	0	0	1	0	1

[Return to Table of Contents](#)

rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo

rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo SNAPSHOT

Drug Name	rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo
Key Synonyms	rituximab
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc;Daiichi Sankyo Co Ltd
Inactive Companies	
Highest Status	Discovery
Active Indications	Hematological neoplasm
Target-based Actions	B-lymphocyte antigen CD20 inhibitor
Other Actions	Anticancer monoclonal antibody
Technologies	Biosimilar product;Biological therapeutic;Intravenous formulation;Infusion;Protein recombinant;Chimeric monoclonal antibody
Last Change Date	21-Jan-2014

rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo DEVELOPMENT PROFILE

SUMMARY

Coherus BioSciences, in collaboration with Asia licensee Daiichi Sankyo, is investigating a biosimilar of rituximab, an anti-CD20 mAb, presumably for the potential iv treatment of hematological malignancies. In March 2013, approval/launch for lymphoma in Japan was expected in 2017.

rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Coherus BioSciences Inc	Hematological neoplasm	US	Discovery	31-Jan-2010
Daiichi Sankyo Co Ltd	Hematological neoplasm	Japan	Discovery	31-Jan-2010
Daiichi Sankyo Co Ltd	Hematological neoplasm	South Korea	Discovery	31-Jan-2010
Daiichi Sankyo Co Ltd	Hematological neoplasm	Taiwan	Discovery	31-Jan-2010

[Return to Table of Contents](#)




rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo DRUG NAMES

Names	Type
rituximab	BANN, INN, USAN
rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo	

rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Coherus BioSciences Inc	1	0	0	0	1
Daiichi Sankyo Co Ltd	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

CHS-002

CHS-002 SNAPSHOT

Drug Name	CHS-002
Key Synonyms	
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	
Other Actions	Unspecified drug target
Technologies	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant
Last Change Date	24-Jul-2014

CHS-002 DEVELOPMENT PROFILE

SUMMARY

Coherus is investigating CHS-002, an undisclosed biosimilar, for the potential treatment of inflammatory disorders and/or cancer. In January 2014, the company planned to initiate a phase I trial in the first quarter of 2014 and complete it in the second quarter of 2014; a phase III study was expected to start in the second quarter of 2015 and complete in the first quarter of 2016. At that time, the company planned to file a marketing application in the second quarter of 2016.

CHS-002 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Coherus BioSciences Inc	Unidentified indication	US	Discovery	21-Jan-2014

CHS-002 DRUG NAMES

Names	Type
CHS-002	Research Code
undisclosed biosimilar, Coherus	

[Return to Table of Contents](#)





CHS-004

CHS-004 SNAPSHOT

Drug Name	CHS-004
Key Synonyms	
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	
Other Actions	Unspecified drug target
Technologies	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant
Last Change Date	24-Jul-2014

CHS-004 DEVELOPMENT PROFILE

SUMMARY

Coherus is investigating CHS-004, an undisclosed biosimilar, for the potential treatment of inflammatory disorders and/or cancer. In January 2014, the company planned to initiate a phase I study in the second quarter of 2015, and complete it in the third quarter of 2015; a phase III study was expected to start in the fourth quarter of 2015 and complete in the first quarter of 2017. At that time, the company also planned to file a marketing application in the first quarter of 2017.

CHS-004 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Coherus BioSciences Inc	Unidentified indication	US	Discovery	21-Jan-2014

CHS-004 DRUG NAMES

Names	Type
CHS-004	Research Code
undisclosed biosimilar, Coherus	

[Return to Table of Contents](#)





CHS-003

CHS-003 SNAPSHOT

Drug Name	CHS-003
Key Synonyms	
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	
Other Actions	Unspecified drug target
Technologies	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant
Last Change Date	24-Jul-2014

CHS-003 DEVELOPMENT PROFILE

SUMMARY

Coherus is investigating CHS-003, an undisclosed biosimilar, for the potential treatment of inflammatory disorders and/or cancer. In January 2014, the company planned to initiate a phase I study in the first quarter of 2014 and complete it in the second quarter of 2014; a phase III study was expected to initiate in the fourth quarter of 2014 and complete in the third quarter of 2015. At that time, the company also planned to file a marketing application in the second quarter of 2016.

CHS-003 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Coherus BioSciences Inc	Unidentified indication	US	Discovery	21-Jan-2014

CHS-003 DRUG NAMES

Names	Type
CHS-003	Research Code
undisclosed biosimilar, Coherus	

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

